ea0090p61 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023
Lisco Giuseppe
, De Tullio Anna
, Disoteo Olga
, De Geronimo Vincenzo
, Piazzolla Giuseppina
, De Pergola Giovanni
, Angelo Giagulli Vito
, Jirillo Emilio
, Guastamacchia Edoardo
, Sabba Carlo
, Triggiani Vincenzo
Tirzepatide, a once-weekly dual co-agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, has been demonstrated to improve glucose control and reduced body weight in different therapeutic approaches. With this rapid review and meta-analysis, we systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin compared to basal insulin plus background treatments titrated rigorously t...